• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Medical Devices

  • Print
  • Share
  • E-mail

Photodynamic Diagnostic D-Light C (PDD) System - P050027

Diagram of the Photodynamic Diagnostic D-Light C (PDD) System. Indicates PPD Cystoscope, D-Light C, Fluid Light Cable, PDD Camera Head, and Camera Control Unit.This is a brief overview of information related to FDA’s approval to market this product. See the links below to the Summary of Safety and Effectiveness Data (SSED) and product labeling for more complete information on this product, its indications for use, and the basis for FDA’s approval. 

Product Name: Karl Storz Photodynamic Diagnostic D-Light C (PDD) System
PMA Applicant: Karl Storz Endoscopy-America, Inc.
Address: 2151 E. Grand Avenue, El Segundo, CA 90245
Approval Date: May 28, 2010
Approval Letter: http://www.accessdata.fda.gov/ cdrh_docs/pdf5/P050027a.pdf

What is it? The Karl Storz Photodynamic Diagnostic D-Light C (PDD) System is used as an optional accessory to white light cystoscopy when used in combination with the diagnostic imaging drug Cysview® (Photocure ASA, a Norwegian pharmaceutical company).

The system includes:

  • D-Light-C light Source and Fluid Light Cable
  • PDD Telescopes (cystoscopes)
  • Endovision Telecam® SL and/or Endovision Tricam® SL Camera Control Unit and PDD Camera Head

How does it work? Light is transmitted through a fluid light cable connected to an endoscope to light up the area to be observed. Blue light is used to excite Cysview® that has collected in cancerous tissue.

When is it used? The D-Light C PDD System when used in combination with the Cysview® is used to detect non-muscle invasive papillary cancer of the bladder.

What will it accomplish? Based on evidence collected during a clinical study, Cysview® plus blue light cystoscopy has been demonstrated to detect non-muscle invasive papillary cancer of the bladder.

When should it not be used?

  • Patients with gross hematuria.
  • Patients with porphyria.
  • Patients that have hypersensitivity to Cysview® solution.
  • Patients who have received BCG immunotherapy or chemotherapy with in the last 90 days.
  • Patients who have received a previous dose of Cysview® solution, as the safety and efficacy of repeated use of Cysview® solution has not been established.

Additional information: Summary of Safety and Effectiveness and labeling are available online.